Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy

LI Fu-xin

doi:10.11653/zgsyfjxzz2013070342

您当前的位置：

首页 >

文章列表页 >

Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy

更新时间：2024-01-04

- Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 7, Pages: 342-345(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/zgsyfjxzz2013070342
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
LI Fu-xin. Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(7): 342-345.
DOI：

LI Fu-xin. Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(7): 342-345. DOI： 10.11653/zgsyfjxzz2013070342.

摘要

目的: 探讨扶正疏肝消癌方对乳腺癌术后放化疗患者复发转移和生存质量的影响。方法: 82例乳腺癌改良根治术患者随机分为观察组43例和对照组39例。对照组采用西医常规对症处理。观察组在此基础上服用自拟扶正疏肝消癌方

自放化疗开始每日1剂至放化疗结束后3个月

其后每周服4～7剂

常规水煎分2次服用

煎煮不便者用配方颗粒。共12个月。评价患者生存质量、主要临床症状和体征

记录复发转移情况

测定血管内皮生长因子(VEGF)。结果: 观察组治疗6

12个月总体健康评分均高于对照组(P<0.01);放化疗结束

治疗6

12个月观察组总体生活质量均高于对照组(P<0.01);观察组在放化疗结束后

治疗6

12个月主要症状、体征记分均低于同期对照组(P<0.01);观察组在治疗6及12个月血清VEGF水平均低于同期对照组(P<0.05

P<0.01)。结论: 扶正疏肝消癌方能减轻乳腺癌术后放化疗患者临床症状和体征

提高患者生存质量

能降低血清VEGF水平

可能有防止乳腺癌复发和转移作用。

Abstract

Objective: To study the influence of Fuzheng Shugan Xiaoai decoction (FSXD) on relapse

metastasis and life quality in breast cancer patients with postoperative radiation and chemotherapy. Method: Eighty-two cases of breast cancer patients after modified radical mastectomy were randomly divided into the observation group (n=43) and the control group (n=39). The control group was given routine western medicine symptomatic treatment. Except the routine symptomatic treatment

the observation group was given FSXD

1 dose daily right after radiotherapy or/and chemotherapy until 3 months after the ending of those therapies. Afterwards

4-7 doses of FSXD per week were given to a patient for 1 year. Generally

a dose of FSXD was decocted and divided in half for 2 services daily. When decoction was inconvenient for some patients

the formulated granules were given. The life quality

the main symptoms and signs

relapse and metastasis were recorded. Vascular endothelial growth factor (VEGF) was determined for the patients. Result: After 6

12 months of treatment

the overall health scores in the observation group were higher than those in the control group (P<0.01). After 6

12 months of treatment

the overall life quality in the observation group was higher than that in the control group (P<0.01). After the ending of radiotherapy and chemotherapy

additional treatment of FXSD for 6

12 months the main symptoms and signs in observation group were lower than those in the control group (P<0.01). The serum VEGF levels in the observation group after treatment of 6 and 12 months were lower than those in the control group

the difference was significant (P<0.05

P<0.01). Conclusion: FSXD can reduce the main symptoms and signs for breast cancer patients with postoperative radiotherapy and chemotherapy

improve the quality of life for the patients

and reduce serum VEGF level. Therefore

FSXD may prevent the recurrence and metastasis of the cancer.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation

Mechanism of Kidney-tonifying and Liver-regulating Cyclical Therapy and Formula in Improving Endometrial Receptivity during "Implantation Window" in Rats with Polycystic Ovary Syndrome via miR-140-5p/VEGF Pathway

Exploring Mechanism of Breast Cancer Prevention by Liuwei Dihuangwan， Erzhiwan and Zuoguiwan Based on Macrophage Phagocytosis

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Intervention of Breast Cancer by Regulating Wnt/β-catenin Signaling Pathway with Traditional Chinese Medicine： A Review

Related Author

SUN Xian-fu

LIU Hui

HE Ya-ning

LIU Chao-jun

CUI Shu-de

LIU Quan

HE Yiqing

ZHANG Ying

Related Institution

Hunan University of Chinese Medicine

Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases， Hunan University of Chinese Medicine

Jiangxi University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

The First Clinical Medical College of Heilongjiang University of Traditional Chinese Medicine （TCM）

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰